Assay for Identification of LRRK2 Inhibitors
AssigneeMedical Research Council
InventorsNicholas Dzamko, Dario Alessi, R. Jeremy Nichols
Life of this patent
Estimating the term…
Loading patent…
AssigneeMedical Research Council
InventorsNicholas Dzamko, Dario Alessi, R. Jeremy Nichols
Estimating the term…
A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.
An antibody that binds specifically to LRRK2 phosphorylated at Ser910;
A kit of parts comprising two or more of:
A purified preparation or kit of parts comprising an LRRK2 polypeptide or polynucleotide or antibody binding specifically to LRRK2;
A method of characterising an LRRK2 mutant, the method comprising the steps of:
Dependencies are inferred from the claim text.